1
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
2
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
3
|
Yamaguchi D, Morisaki T, Sakata Y, Mizuta Y, Nagatsuma G, Inoue S, Shimakura A, Jubashi A, Takeuchi Y, Ikeda K, Tanaka Y, Yoshioka W, Hino N, Ario K, Tsunada S, Esaki M. Usefulness of discharge standards in outpatients undergoing sedative endoscopy: a propensity score-matched study of the modified post-anesthetic discharge scoring system and the modified Aldrete score. BMC Gastroenterol 2022; 22:445. [PMCID: PMC9635164 DOI: 10.1186/s12876-022-02549-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Accepted: 10/20/2022] [Indexed: 11/06/2022] Open
Abstract
Background This study aimed to evaluate the usefulness of discharge standards in outpatients undergoing sedative endoscopy by comparing the modified post-anesthetic discharge scoring system (MPADSS) and the modified Aldrete score. Methods We prospectively enrolled 376 outpatients who underwent gastrointestinal endoscopy under midazolam sedation; 181 outpatients were assessed regarding discharge after sedative endoscopy using the MPADSS (group M), and 195 patients were assessed by the modified Aldrete score (group A). The clinical characteristics, types of endoscopy, endoscopic outcomes, and anesthesia outcomes were evaluated between the two groups. We compared discharge score, recovery time, and adverse events using propensity-score matching. Results Propensity-score matching created 120 matched pairs. The proportion of patients who had a recovery time within 60 min after endoscopy was significantly higher in group A than that in group M (42.5% versus 25.0%, respectively; P < 0.01). The proportion of patients who required > 120 min of recovery time after endoscopy was significantly lower in group A than that in group M (0.0% versus 5.0%, respectively; P = 0.03). However, significantly more patients had drowsiness at discharge in group A compared with group M (19.1% versus 5.0%, respectively; P < 0.01). There was no significant difference in the adverse event rate within 24 h of discharge between the groups. Conclusions Patients assessed by the modified Aldrete score were allowed to discharge earlier than those assessed by the MPADSS. However, a patient’s level of consciousness should be assessed carefully, especially in patients who visit the hospital alone. Supplementary Information The online version contains supplementary material available at 10.1186/s12876-022-02549-7.
Collapse
Affiliation(s)
- Daisuke Yamaguchi
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan ,grid.412339.e0000 0001 1172 4459Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga, 849-8501 Japan
| | - Tomohito Morisaki
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan ,Department of Gastroenterology, Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan
| | - Yasuhisa Sakata
- grid.412339.e0000 0001 1172 4459Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga, 849-8501 Japan
| | - Yumi Mizuta
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Goshi Nagatsuma
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Suma Inoue
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Akane Shimakura
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Amane Jubashi
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuki Takeuchi
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Kei Ikeda
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuichiro Tanaka
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Wataru Yoshioka
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Naoyuki Hino
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Keisuke Ario
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Seiji Tsunada
- grid.440125.6Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Motohiro Esaki
- grid.412339.e0000 0001 1172 4459Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga, 849-8501 Japan
| |
Collapse
|
4
|
Kurumi H, Takata T, Kanda T, Sugihara T, Kakugawa T, Yokota SI, Morisaki T, Akashi T, Isomoto H. Investigating the role of heat shock protein 47 in fibrosis in Crohn's disease. Sci Rep 2022; 12:10966. [PMID: 35768471 PMCID: PMC9243024 DOI: 10.1038/s41598-022-15153-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 06/20/2022] [Indexed: 12/15/2022] Open
Abstract
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract that share similar genetic risk factors. However, while fibrotic stricture of the intestine is a major characteristic of CD; it is rarely observed in UC. Deposition of collagen in the extracellular matrix contributes to the formation of fibrotic strictures in CD, but the underlying mechanisms are unknown. In the present study, we found that heat shock protein 47 (HSP47), a stress-response protein that acts as a molecular chaperone during the processing and secretion of collagen, expressed in the intestinal tissue from patients with CD. Serum HSP47 levels and anti-HSP47 antibody titers were significantly higher in patients with CD than in those with UC. Furthermore, anti-HSP47 antibody levels correlated significantly with fibrosis in CD. In addition, HSP47 inhibition significantly suppressed collagen production in fibroblasts in vitro. These findings suggest that HSP47 is a biomarker for differentiating fibrotic from non-fibrotic forms of CD. Additionally, we propose that HSP47 could be a potential target for treating fibrosis in patients with CD.
Collapse
Affiliation(s)
- Hiroki Kurumi
- Division of Gastroenterology and Nephrology, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Tomoaki Takata
- Division of Gastroenterology and Nephrology, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago, Tottori, 683-8504, Japan.
| | - Tsutomu Kanda
- Division of Gastroenterology and Nephrology, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Takaaki Sugihara
- Division of Gastroenterology and Nephrology, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago, Tottori, 683-8504, Japan
| | - Tomoyuki Kakugawa
- Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University, 1-1-1, Minamikogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Shin-Ichi Yokota
- Department of Microbiology, Sapporo Medical University School of Medicine, Minami-1-jo-Nishi-17, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan
| | - Tomohito Morisaki
- Department of Endoscopy, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan
| | - Taro Akashi
- Department of Endoscopy, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan
| | - Hajime Isomoto
- Division of Gastroenterology and Nephrology, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago, Tottori, 683-8504, Japan. .,Department of Endoscopy, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.
| |
Collapse
|
5
|
Warmer F, Tanaka K, Xanthopoulos P, Nunami M, Nakata M, Beidler CD, Bozhenkov SA, Beurskens MNA, Brunner KJ, Ford OP, Fuchert G, Funaba H, Geiger J, Gradic D, Ida K, Igami H, Kubo S, Langenberg A, Laqua HP, Lazerson S, Morisaki T, Osakabe M, Pablant N, Pasch E, Peterson B, Satake S, Seki R, Shimozuma T, Smith HM, Stange T, Stechow AV, Sugama H, Suzuki Y, Takahashi H, Tokuzawa T, Tsujimura T, Turkin Y, Wolf RC, Yamada I, Yanai R, Yasuhara R, Yokoyama M, Yoshimura Y, Yoshinuma M, Zhang D. Impact of Magnetic Field Configuration on Heat Transport in Stellarators and Heliotrons. Phys Rev Lett 2021; 127:225001. [PMID: 34889640 DOI: 10.1103/physrevlett.127.225001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 07/30/2021] [Accepted: 09/20/2021] [Indexed: 06/13/2023]
Abstract
We assess the magnetic field configuration in modern fusion devices by comparing experiments with the same heating power, between a stellarator and a heliotron. The key role of turbulence is evident in the optimized stellarator, while neoclassical processes largely determine the transport in the heliotron device. Gyrokinetic simulations elucidate the underlying mechanisms promoting stronger ion scale turbulence in the stellarator. Similar plasma performances in these experiments suggests that neoclassical and turbulent transport should both be optimized in next step reactor designs.
Collapse
Affiliation(s)
- Felix Warmer
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Tanaka
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Kyushu University, Interdisciplinary Graduate School of Engineering Sciences, Plasma and Quantum Science and Engineering, Kasuga, Fukuoka 816-8580, Japan
| | - P Xanthopoulos
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M Nunami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - M Nakata
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - C D Beidler
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S A Bozhenkov
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M N A Beurskens
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K J Brunner
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - O P Ford
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - G Fuchert
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Funaba
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - J Geiger
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - D Gradic
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Ida
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Igami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Kubo
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - A Langenberg
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H P Laqua
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S Lazerson
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Morisaki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - N Pablant
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - E Pasch
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - B Peterson
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Satake
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - R Seki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Shimozuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - H M Smith
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Stange
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - A V Stechow
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Sugama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Suzuki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Takahashi
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tsujimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Turkin
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - R C Wolf
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - I Yamada
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yanai
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yasuhara
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Yokoyama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Yoshimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - D Zhang
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| |
Collapse
|
6
|
Jubashi A, Yamaguchi D, Ogata R, Nagatsuma G, Hara Y, Tanaka Y, Yoshioka W, Hino N, Morisaki T, Ario K, Matsuoka Y, Taba M, Naito S, Tsunada S. A case of pancreatic endocrine carcinoma with a different clinical diagnosis before chemotherapy and pathological autopsy. Clin J Gastroenterol 2021; 15:237-243. [PMID: 34689312 DOI: 10.1007/s12328-021-01538-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Accepted: 10/14/2021] [Indexed: 11/29/2022]
Abstract
We encountered a case of pancreatic neuroendocrine carcinoma (pNEC) diagnosed via pathological autopsy that was initially diagnosed clinically as G3 pancreatic neuroendocrine tumor (G3 pNET) and discussed the differences between these entities in the literature. A 76-year-old man was admitted to our department because of jaundice. Computed tomography revealed multiple round nodules in both lung fields, suggesting metastasis, and a mass lesion was detected in the head of the pancreas with poor contrast in the arterial phase and slight contrast enhancement in the equilibrium phase. Biopsy of the lungs and pancreas led to a diagnosis of multiple pulmonary metastases of G3 pNET. Because the lesions were unresectable, chemotherapy was administered. Treatment was started with everolimus for 5 weeks. However, the patient experienced severe loss of appetite and malaise, and the lung lesions progressed, prompting treatment discontinuation. Subsequently, the patient's disease progressed rapidly, and he died 99 days after the start of chemotherapy. We performed a pathological autopsy with the consent of the family because of the rapid tumor growth. A pathological autopsy revealed a final diagnosis of pNEC, which differed from the clinical diagnosis.
Collapse
Affiliation(s)
- Amane Jubashi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.,Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan. .,Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga, 849-8501, Japan.
| | - Ryo Ogata
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Goshi Nagatsuma
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yumi Hara
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuichiro Tanaka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Wataru Yoshioka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Naoyuki Hino
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuki Matsuoka
- Department of Pathology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Mitsuru Taba
- Department of Pathology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Shinji Naito
- Department of Pathology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| |
Collapse
|
7
|
Saiki R, Momozawa Y, Nannya Y, Nakagawa M, Ochi Y, Yoshizato T, Terao C, Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T, Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S. Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106679.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Akazawa Y, Morisaki T, Fukuda H, Norimatsu K, Shiota J, Hashiguchi K, Tabuchi M, Kitayama M, Matsushima K, Yamaguchi N, Kondo H, Fujita F, Takeshita H, Nakao K, Takeshima F. Significance of serum palmitoleic acid levels in inflammatory bowel disease. Sci Rep 2021; 11:16260. [PMID: 34376800 PMCID: PMC8355139 DOI: 10.1038/s41598-021-95923-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 06/28/2021] [Indexed: 01/22/2023] Open
Abstract
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic intestinal diseases of unknown etiology that present with variable disease extents and outcomes. The use of biomarkers for the diagnosis and management of IBDs is considered beneficial. Palmitoleic acid (PO) is an adipose tissue-derived mono-unsaturated free fatty acid that potentially serves as a lipokine in metabolic and inflammatory diseases. The aim of this study was to investigate the significance of PO levels in the serum of patients with UC and CD. The study included patients with UC (n = 22), patients with CD (n = 35), and controls (n = 22). The levels of serum PO were analyzed using gas chromatography. The association of serum PO levels with the clinical features and disease outcomes in IBD was examined. Serum PO levels were significantly higher in patients with CD than in controls, whereas no difference in these levels was observed between patients with UC and controls. Serum PO levels were significantly associated with the CD activity index. Additionally, high serum PO levels were associated with an increased risk of surgical intervention requirement during follow-up. In a pilot study with a few patients, high PO levels were observed in the mesenteric tissue in the active disease site of patients with CD (n = 7) compared with those with colon cancer (n = 6). Elevated serum PO levels might serve as a marker for local inflammation and prognosis in patients with CD.
Collapse
Affiliation(s)
- Yuko Akazawa
- Tissue and Histopathology Section, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
| | | | | | - Kiyuu Norimatsu
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Junya Shiota
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Keiichi Hashiguchi
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Maiko Tabuchi
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Moto Kitayama
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Kayoko Matsushima
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Naoyuki Yamaguchi
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Hisayoshi Kondo
- Biostatistics Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Medicine, Nagasaki, Japan
| | | | | | - Kazuhiko Nakao
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Fuminao Takeshima
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Nagasaki Goto Chuoh Hospital, Goto, Japan
| |
Collapse
|
9
|
Takeuchi Y, Yamaguchi D, Yamaguchi N, Ikeda K, Yoshioka W, Fukuda H, Morisaki T, Ario K, Tsunada S, Katsuki R, Tominaga N, Yamasaki S, Eguchi Y, Ogata S, Fujimoto K. Propofol Sedation in the Endoscopy Room versus Operation Room during Endoscopic Submucosal Dissection for Gastric Tumors: A Propensity Score-Matching Analysis. Digestion 2021; 101:450-457. [PMID: 31129673 DOI: 10.1159/000500874] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 05/07/2019] [Indexed: 02/04/2023]
Abstract
BACKGROUND/AIMS The present study was performed to compare the safety of sedation with propofol during endoscopic submucosal dissection (ESD) for gastric tumors under sedation in the endoscopy room by an endoscopist versus sedation in the operation room by an anesthesiologist. METHODS In total, 638 patients with gastric tumors who underwent ESD from January 2011 to August 2017 at Ureshino Medical Center and Saga Medical Center Koseikan were retrospectively reviewed. The patients were divided into 2 groups: those who underwent ESD in the endoscopy room (Group E, n = 532) and those who underwent ESD in the operation room (Group O, n = 106). Propensity score matching was applied for evaluation. The treatment outcome of ESD and the adverse events of sedation during ESD (desaturation, hypotension, bradycardia, and arrhythmia) were compared between the 2 groups to consider the safety of ESD. RESULTS The propensity score-matching analysis created 82 matched pairs. Adjusted comparisons between Groups E and O showed similar treatment outcomes of ESD for gastric tumors. There were no significant differences in the treatment outcomes, anesthesia time, and mean propofol dose between the 2 groups. With respect to adverse events, desaturation occurred more often in Group E than Group O (18.3 vs. 3.7%, respectively; p = 0.005). There were no significant differences in other adverse events (hypotension, bradycardia, and arrhythmia) between the 2 groups. CONCLUSION Sedation with propofol in the operation room might be required to ensure safer application of ESD for gastric tumors. However, a decrease in the desaturation rate was the only disadvantage of sedation in the endoscopy room.
Collapse
Affiliation(s)
- Yuki Takeuchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan.,Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan, .,Department of Internal Medicine, Saga Medical School, Saga, Japan,
| | - Naoko Yamaguchi
- Department of Anesthesiology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Kei Ikeda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Wataru Yoshioka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Hiroko Fukuda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Ryo Katsuki
- Department of Anesthesiology, National Hospital Organization Ureshino Medical Center, Saga, Japan
| | - Naoyuki Tominaga
- Department of Gastroenterology, Saga Medical Center Kouseikan, Saga, Japan
| | - Satoko Yamasaki
- Department of Gastroenterology, Saga Medical Center Kouseikan, Saga, Japan
| | - Yuichiro Eguchi
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Shinichi Ogata
- Department of Gastroenterology, Saga Medical Center Kouseikan, Saga, Japan
| | - Kazuma Fujimoto
- Department of Internal Medicine, Saga Medical School, Saga, Japan.,International University of Health and Welfare Graduate School, Fukuoka, Japan
| |
Collapse
|
10
|
Jubashi A, Yamaguchi D, Nagatsuma G, Inoue S, Tanaka Y, Yoshioka W, Hino N, Morisaki T, Ario K, Fukui K, Ishimaru H, Tsunada S. Successful retrograde transvenous embolization under balloon occlusion for rectal arteriovenous malformation. Clin J Gastroenterol 2021; 14:594-598. [PMID: 33420667 PMCID: PMC8016791 DOI: 10.1007/s12328-020-01335-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 12/25/2020] [Indexed: 11/29/2022]
Abstract
A 57-year-old man was admitted to our hospital because of frequent hematochezia. Colonoscopy exhibited a submucosal tumor-like lesion in the lower rectum. Abdominal contrast-enhanced computed tomography showed a rectal arteriovenous malformation (AVM) on the right side wall of the lower rectum. The feeder was the superior rectal artery, with early venous return. Embolization of the draining vein and feeding artery of the AVM with N-butyl-2-cyanoacrylate under balloon occlusion was planned. Angiography of the superior rectal artery showed the nidus in the rectum with early venous return of contrast material. The portal vein was punctured percutaneously under ultrasound guidance, and a balloon catheter advanced to the distal part of the superior rectal vein. Venography under balloon occlusion showed the outflow vein and nidus. Transvenous and transarterial nidus embolization with N-butyl-2-cyanoacrylate under balloon occlusion was then performed. Since the embolization, there have been no further episodes of bleeding. There is no established treatment for AVMs. Successful treatment requires targeting and eradication of the nidus. We successfully performed embolization therapy for a rectal AVM via a retrograde transvenous approach. This technique may be suitable for completely eradicating the nidus without the risk of embolism.
Collapse
Affiliation(s)
- Amane Jubashi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Saga University, Saga, 849-8501, Japan.
| | - Goshi Nagatsuma
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Suma Inoue
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuichiro Tanaka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Wataru Yoshioka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Naoyuki Hino
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Kenichiro Fukui
- Department of Radiology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | | | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| |
Collapse
|
11
|
Peterson B, Kawamura G, van de Giessen P, Mukai K, Tanaka H, Sano R, Pandya S, Dai S, Masuzaki S, Akiyama T, Kobayashi M, Goto M, Motojima G, Sakamoto R, Ohno N, Morisaki T, Miyazawa J. Experimental observations and modelling of radiation asymmetries during N2 seeding in LHD. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2020.100848] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Nespoli F, Ashikawa N, Gilson E, Lunsford R, Masuzaki S, Shoji M, Oishi T, Suzuki C, Nagy A, Mollen A, Pablant N, Ida K, Yoshinuma M, Tamura N, Gates D, Morisaki T. First impurity powder injection experiments in LHD. Nuclear Materials and Energy 2020. [DOI: 10.1016/j.nme.2020.100842] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020; 10:12546. [PMID: 32719413 PMCID: PMC7385627 DOI: 10.1038/s41598-020-68828-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 07/02/2020] [Indexed: 02/07/2023] Open
Abstract
While retrospective studies have compared the efficacy of anti–tumour necrosis factor (TNF) agents and tacrolimus (TAC) in ulcerative colitis (UC), information regarding first-time use of these agents is limited. The aim of our study was to investigate the short- and long-term efficacy of anti-TNF agents [adalimumab (ADA) and infliximab (IFX)] and TAC in anti-TNF agent- and TAC-naïve steroid-refractory UC patients. We evaluated 150 steroid-refractory UC patients receiving anti-TNF agents (IFX: n = 30, ADA: n = 41) or TAC (n = 79) at eight institutions in Japan. Clinical response rates at 8 weeks were 73.2% and 75.9% while remission rates were 30.1% and 25.3% in the anti-TNF and TAC groups, respectively. Logistic regression analysis showed the male sex and higher C-reactive protein to be independent factors for response to anti-TNF agents and TAC, respectively. Use of TAC was an independent factor for relapse. No differences in response to the treatment or relapse were observed between IFX and ADA. In conclusion, TAC and anti-TNF agents promoted similar short-term effects, but anti-TNF agents ensured better long-term outcomes at first-time treatment of steroid-refractory UC patients.
Collapse
Affiliation(s)
- Moto Kitayama
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Yuko Akazawa
- Tissue and Histopathology Section, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki City, Japan
| | - Daisuke Yoshikawa
- Department of Gastroenterology and Hepatology, Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo City, Nagasaki, 857-8511, Japan
| | - Shuntaro Higashi
- Department of Gastroenterology, Inoue Hospital, 6-12, Takaramachi, Nagasaki City, Nagasaki, 850-0045, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology and Hepatology, National Hospital Organization Ureshino Medical Center, 2436 Ureshino-cho, Ureshino City, Saga, 843-0393, Japan
| | - Hidetoshi Oda
- Department of Gastroenterology and Hepatology, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo City, Nagasaki, 857-1195, Japan
| | - Maho Ikeda
- Department of Internal Medicine, Juko Memorial Nagasaki Hospital, 6-17, Maruo, Nagasaki City, Nagasaki, 852-8004, Japan
| | - Yujiro Nakashima
- Department of Gastroenterology, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Ohmura City, Nagasaki, 856-8562, Japan
| | - Maiko Tabuchi
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Keiichi Hashiguchi
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Kayoko Matsushima
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Naoyuki Yamaguchi
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Hisayoshi Kondo
- Biostatistics Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| | - Kazuhiko Nakao
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Fuminao Takeshima
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan. .,Department of Internal Medicine, Nagasaki Prefecture Goto Central Hospital, 205 Yoshikugi, Goto City, Nagasaki, 853-0031, Japan.
| |
Collapse
|
14
|
Yamaguchi D, Yoshida H, Ikeda K, Takeuchi Y, Yamashita S, Jubashi A, Yukimoto T, Takeshita E, Yoshioka W, Fukuda H, Tominaga N, Tsuruoka N, Morisaki T, Ario K, Tsunada S, Fujimoto K. Colorectal endoscopic mucosal resection with submucosal injection of epinephrine versus hypertonic saline in patients taking antithrombotic agents: propensity-score-matching analysis. BMC Gastroenterol 2019; 19:192. [PMID: 31744465 PMCID: PMC6862827 DOI: 10.1186/s12876-019-1114-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Accepted: 11/11/2019] [Indexed: 02/07/2023] Open
Abstract
Background Endoscopic mucosal resection (EMR) to remove colon polyps is increasingly common in patients taking antithrombotic agents. The safety of EMR with submucosal saline injection has not been clearly demonstrated in this population. Aims The present study aimed to evaluate the efficacy and safety of submucosal injection of saline–epinephrine versus hypertonic saline in colorectal EMR of patients taking antithrombotic agents. Methods This study enrolled 204 patients taking antithrombotic agents among 995 consecutive patients who underwent colonic EMR from April 2012 to March 2018 at Ureshino Medical Center. Patients were divided into two groups according to the injected solution: saline–epinephrine or hypertonic (10%) saline (n = 102 in each group). Treatment outcomes and adverse events were evaluated in each group and risk factors for immediate and post-EMR bleeding were investigated. Results There were no differences between groups in patient or polyp characteristics. The main antithrombotic agents were low-dose aspirin, warfarin, and clopidogrel. Propensity-score matching created 80 matched pairs. Adjusted comparisons between groups showed similar en bloc resection rates (95.1% with saline–epinephrine vs. 98.0% with hypertonic saline). There were no significant differences in adverse events (immediate EMR bleeding, post-EMR bleeding, perforation, or mortality) between groups. Multivariate analyses revealed that polyp size over 10 mm was associated with an increased risk of immediate EMR bleeding (odds ratio 12.1, 95% confidence interval 2.0–74.0; P = 0.001). Conclusions Two tested solutions in colorectal EMR were considered to be both safe and effective in patients taking antithrombotic agents.
Collapse
Affiliation(s)
- Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan. .,Department of Internal Medicine, Saga Medical School, Saga, Japan.
| | - Hisako Yoshida
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Kei Ikeda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuki Takeuchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Shota Yamashita
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Amane Jubashi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | | | - Eri Takeshita
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Wataru Yoshioka
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Hiroko Fukuda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Naoyuki Tominaga
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Nanae Tsuruoka
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Kazuma Fujimoto
- Department of Internal Medicine, Saga Medical School, Saga, Japan.,Faculty of Medicine, International University of Health and Welfare, Fukuoka, Japan
| |
Collapse
|
15
|
Kashiwagi S, Asano Y, Kouhashi R, Ishihara S, Tauchi Y, Morisaki T, Noda S, Takashima T, Onoda N, Hirakawa K, Ohira M. Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz416.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Asano Y, Kashiwagi S, Kouhashi R, Ishihara S, Tauchi Y, Morisaki T, Noda S, Takashima T, Onoda N, Hirakawa K, Ohira M. Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz417.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Motojima G, Murase T, Shoji M, Ogawa H, Yokota M, Maccallini E, Siviero F, Ferrara A, Mura M, Sakurai H, Masuzaki S, Morisaki T. New installation of in-vessel Non Evaporable Getter (NEG) pumps for the divertor pump in the LHD. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.03.164] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Shoji M, Kawamura G, Masuzaki S, Morisaki T. Impurity transport simulation in the peripheral plasma in the large helical device with tungsten closed helical divertor. Nuclear Materials and Energy 2018. [DOI: 10.1016/j.nme.2018.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Takada K, Kashiwagi S, Fukui Y, Goto W, Asano Y, Morisaki T, Takashima T, Hirakawa K, Ohira M. Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy. BJS Open 2018; 3:38-47. [PMID: 30734014 PMCID: PMC6354182 DOI: 10.1002/bjs5.50108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 08/24/2018] [Indexed: 11/12/2022] Open
Abstract
Background Recently, evaluation of quality of life (QOL) has been recognized as a significant outcome measure in the treatment of several cancers. In this study, the Anti-Cancer Drugs-Breast (ACD-B) QOL score was used to assess disease-specific survival in women with breast cancer undergoing preoperative chemotherapy (POC). Methods QOL-ACD-B scores were evaluated before and after POC. The cut-off value of QOL-ACD-B contributing to events such as relapse or death was calculated by receiver operating characteristic (ROC) curve analysis. Results In 300 women with breast cancer treated with POC, QOL was significantly reduced (P < 0·001). A high QOL-ACD-B score before POC was an independent factor in the multivariable analysis of overall survival (hazard ratio 0·26, 95 per cent c.i. 0·04 to 0·96). Conclusion Evaluation by QOL-ACD-B before POC may be useful to predict the prognosis of patients with breast cancer undergoing POC.
Collapse
Affiliation(s)
- K Takada
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - S Kashiwagi
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - Y Fukui
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - W Goto
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - Y Asano
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - T Morisaki
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - T Takashima
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - K Hirakawa
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| | - M Ohira
- Department of Surgical Oncology Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku Osaka 545-8585 Japan
| |
Collapse
|
20
|
Yamaguchi D, Ikeda K, Takeuchi Y, Kinoshita R, Higuchi T, Fukuda H, Tominaga N, Morisaki T, Ario K, Tsunada S, Yoshida H, Fujimoto K. New insertion method of transnasal ileus tube for small bowel obstruction: Anterior balloon method. PLoS One 2018; 13:e0207099. [PMID: 30462677 PMCID: PMC6248956 DOI: 10.1371/journal.pone.0207099] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 10/24/2018] [Indexed: 11/20/2022] Open
Abstract
Background Small bowel obstruction (SBO) is usually caused by postoperative adhesions and malignant disease, and decompression is effective for SBO. Our previous case report suggested that a new transnasal ileus tube insertion method, the anterior balloon method (ABM), could achieve decompression for adhesive SBO. Aims The study aimed to investigate the effectiveness of a new method for inserting transnasal ileus tubes in patients with SBO. Methods Altogether, 134 patients with small bowel obstruction treated from January 2011 to December 2017 were reviewed. The patients were categorized into two groups: those with the new method that inserts an anterior balloon (ABM group: 52 patients, 2014–2017) versus those with the ordinary insertion method (OIM group: 82 patients, 2011–2014). Results The patients’ characteristics and symptoms on admission were similar in the ABM and OIM groups. Adhesions were the main cause of ileus in the two groups. The insertion time duration was significantly shorter in the ABM group than in OIM group (28.4 ± 9.1 vs. 33.5 ± 13.0 min; p = 0.01). The ABM group also had significantly longer tubes than OIM group (222.4 ± 32.2 vs. 157.4 ± 31.7 cm; p < 0.001), which resulted in a significantly shorter time until clinical symptoms were relieved in ABM group. There were no significant differences in adverse events between the two groups. Conclusions The ABM group had shorter insertion duration and longer tubes than those of OIM group. The ABM might become a preferred therapeutic choice to achieve decompression in patients with SBO.
Collapse
Affiliation(s)
- Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
- Department of Internal Medicine, Saga Medical School, Saga, Japan
- * E-mail:
| | - Kei Ikeda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Yuki Takeuchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Rikako Kinoshita
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Toru Higuchi
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Hiroko Fukuda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Naoyuki Tominaga
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Hisako Yoshida
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Kazuma Fujimoto
- Department of Internal Medicine, Saga Medical School, Saga, Japan
| |
Collapse
|
21
|
Yukimoto T, Morisaki T, Komukai S, Yoshida H, Yamaguchi D, Tsuruoka N, Miyahara K, Sakata Y, Shibasaki S, Tsunada S, Noda T, Yunotani S, Fujimoto K. The Palliative Effect of Endoscopic Uncovered Self-expandable Metallic Stent Placement Versus Gastrojejunostomy on Malignant Gastric Outlet Obstruction: A Pilot Study with a Retrospective Chart Review in Saga, Japan. Intern Med 2018; 57:1517-1521. [PMID: 29434131 PMCID: PMC6028667 DOI: 10.2169/internalmedicine.0171-17] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Objective Endoscopic self-expandable metallic stent (SEMS) placement and gastrojejunostomy (GJY) are palliative treatments for malignant gastric outlet obstruction (GOO). The aim of the present study was to compare the palliative effects of these treatments and identify predictors of a poor oral intake after treatment. Methods and Patients In total, 65 patients with GOO at multiple centers in Saga, Japan, were evaluated. Thirty-eight patients underwent SEMS placement, and 27 underwent GJY from January 2010 to December 2016. The characteristics and outcomes of the two groups were compared to detect predictors of treatment failure. Results No significant differences in the technical success, clinical success, post-treatment total protein, hospital discharge, duration from eating disability to death, or post-treatment overall survival were present between the SEMS and GJY groups. More patients in the GJY group than in the SEMS group received chemotherapy (51.4% vs. 26.3%, respectively; p=0.042). The period from treatment to the first meal was longer in the GJY group than in the SEMS group (4.5 vs. 3.0 days, respectively; p=0.013). The present study did not identify any risk factors for failure of SEMS placement. Although the stent length tended to be associated with a poor prognosis, the correlation was not statistically significant (odds ratio: 0.60, 95% confidence interval: 0.36-1.01, p=0.053). Conclusion Patients with GOO started meals more promptly after SEMS than after GJY, but the clinical outcomes were not markedly different between the SEMS and GJY groups. These findings suggest that endoscopic uncovered SEMS placement might be a feasible palliative treatment for GOO.
Collapse
Affiliation(s)
- Takahiro Yukimoto
- Departments of Gastroenterology, National Hospital Organization Ureshino Medical Center, Japan
- Department of Internal Medicine, Saga Medical School, Japan
| | - Tomohito Morisaki
- Departments of Gastroenterology, National Hospital Organization Ureshino Medical Center, Japan
| | - Sho Komukai
- Department of Clinical Research Center, Saga Medical School, Japan
| | - Hisako Yoshida
- Department of Clinical Research Center, Saga Medical School, Japan
| | - Daisuke Yamaguchi
- Departments of Gastroenterology, National Hospital Organization Ureshino Medical Center, Japan
| | - Nanae Tsuruoka
- Department of Internal Medicine, Saga Medical School, Japan
| | - Koichi Miyahara
- Departments of Gastroenterology, Karatsu Red Cross Hospital, Japan
| | | | - Shinichi Shibasaki
- Departments of Surgery, National Hospital Organization Ureshino Medical Center, Japan
| | - Seiji Tsunada
- Departments of Gastroenterology, National Hospital Organization Ureshino Medical Center, Japan
| | - Takahiro Noda
- Departments of Gastroenterology, Karatsu Red Cross Hospital, Japan
| | | | | |
Collapse
|
22
|
Affiliation(s)
- Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.,Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan
| |
Collapse
|
23
|
Yamaguchi D, Yamaguchi N, Takeuchi Y, Yukimoto T, Ikeda K, Matsumoto K, Kinoshita R, Kamachi S, Sugiyama K, Morisaki T, Ario K, Yoshida H, Katsuki R, Tsunada S, Fujimoto K. Comparison of sedation between the endoscopy room and operation room during endoscopic submucosal dissection for neoplasms in the upper gastrointestinal tract. BMC Gastroenterol 2017; 17:127. [PMID: 29179691 PMCID: PMC5704549 DOI: 10.1186/s12876-017-0692-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Accepted: 11/17/2017] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The present study was performed to compare the safety of sedation during endoscopic submucosal dissection (ESD) in the endoscopy room versus operation room. METHODS In total, 297 patients with gastrointestinal tumors who underwent ESD from January 2011 to December 2016 were retrospectively reviewed. The patients were divided into two groups: those who underwent ESD in the endoscopy room without propofol (Group E) versus operation room with propofol (Group O). The patient, tumor, and procedure characteristics; adverse events; and treatment outcomes were compared between the two groups. RESULTS The patient and tumor characteristics, including age (73.6 ± 8.2 vs. 72.5 ± 9.1 years), comorbidities, and tumor size and histology, were not different between Groups E and O. The ESD procedure time was comparable between Groups E and O (105.4 ± 70.4 vs. 106.5 ± 64.4 min), and the anesthesia time was equivalent (138.3 ± 78.1 vs. 148.4 ± 68.8 min). There were no significant differences in adverse events between the two groups. During the ESD procedure, desaturation occurred significantly more often in Group E than O (12.9% vs. 4.0%, P = 0.021, odds ratio: 3.53, 95% CI: 1.17-14.4). The recovery time after ESD was significantly longer in Group E than O (180 (100-360) vs. 90 (0-180) min, P < 0.001). CONCLUSIONS A decreased desaturation rate and shorter recovery time after ESD were the advantages of sedation in the operation room with propofol compared with sedation in the endoscopy room. These findings warrant further exploration of the advantages of safe and effective ESD for upper gastrointestinal neoplasms in the operation room.
Collapse
Affiliation(s)
- Daisuke Yamaguchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
- Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, 849-8501 Japan
| | - Naoko Yamaguchi
- Department of Anesthesiology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Yuki Takeuchi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
- Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, 849-8501 Japan
| | - Takahiro Yukimoto
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
- Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, 849-8501 Japan
| | - Kei Ikeda
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Kosuke Matsumoto
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Rikako Kinoshita
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Saori Kamachi
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Kyosuke Sugiyama
- Department of Anesthesiology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Tomohito Morisaki
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Keisuke Ario
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Hisako Yoshida
- Clinical Research Center, Saga Medical School, Saga, 849-8501 Japan
| | - Ryo Katsuki
- Department of Anesthesiology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Seiji Tsunada
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, 843-0301 Japan
| | - Kazuma Fujimoto
- Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, 849-8501 Japan
| |
Collapse
|
24
|
Kashiwagi S, Asano Y, Goto W, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Hirakawa K, Ohira M. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes within fibrotic foci of tumor stroma (FF-TILs). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx655.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Takada K, Kashiwagi S, Goto W, Asano Y, Takashima T, Morisaki T, Noda S, Onoda N, Hirakawa K, Ohira M. Biomarker analysis of TPD regimen (trastuzumab, ertuzumab and docetaxel) for advanced HER2-positive breast cancer by HER family expression. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx653.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Motojima G, Yoshida N, Masuzaki S, Sakamoto R, Tokitani M, Tanaka H, Murase T, Nagata D, Matsumoto K, Miyamoto M, Yajima M, Sakamoto M, Yamada H, Morisaki T. Wide-range evaluation of the deposition layer thickness distribution on the first wall by reflection coefficient measurements. Nuclear Materials and Energy 2017. [DOI: 10.1016/j.nme.2017.04.018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Tanaka H, Kawamura G, Masuzaki S, Kobayashi M, Akiyama T, Peterson B, Mukai K, Sano R, Dai S, Sakamoto R, Morisaki T, Ohno N. Toroidally symmetric/asymmetric effect on the divertor flux due to neon/nitrogen seeding in LHD. Nuclear Materials and Energy 2017. [DOI: 10.1016/j.nme.2016.12.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Nakamura Y, Tamura N, Kobayashi M, Yoshimura S, Suzuki C, Yoshinuma M, Goto M, Motojima G, Nagaoka K, Tanaka K, Sakamoto R, Peterson B, Ida K, Osakabe M, Morisaki T. A comprehensive study on impurity behavior in LHD long pulse discharges. Nuclear Materials and Energy 2017. [DOI: 10.1016/j.nme.2016.11.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Osakabe M, Takeiri Y, Morisaki T, Motojima G, Ogawa K, Isobe M, Tanaka M, Murakami S, Shimizu A, Nagaoka K, Takahashi H, Nagasaki K, Takahashi H, Fujita T, Oya Y, Sakamoto M, Ueda Y, Akiyama T, Kasahara H, Sakakibara S, Sakamoto R, Tokitani M, Yamada H, Yokoyama M, Yoshimura Y. Current Status of Large Helical Device and Its Prospect for Deuterium Experiment. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1335145] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M. Osakabe
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - G. Motojima
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K. Ogawa
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Mechanical Engineering and Science, Kyoto 615-8540, Japan
| | - A. Shimizu
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - H. Takahashi
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K. Nagasaki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Kyoto 611-0011, Japan
| | - H. Takahashi
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T. Fujita
- Nagoya University, Department of Energy Engineering and Science, Graduate School of Engineering, Furo-cho, Chikusa-ku, Nagoya 464-8093, Japan
| | - Y. Oya
- Shizuoka University, Radioscience Research Laboratory, Faculty of Science, 836, Ohya, Suruga-ku, Shizuoka 422-8529, Japan
| | - M. Sakamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Ueda
- Osaka University, Graduate School of Engineering, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - T. Akiyama
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - H. Kasahara
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - S Sakakibara
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M. Tokitani
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Natural Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | | |
Collapse
|
30
|
Komori A, Morisaki T, Mutoh T, Sakakibara S, Takeiri Y, Kumazawa R, Kubo S, Ida K, Morita S, Narihara K, Shimozuma T, Tanaka K, Watanabe KY, Yamada H, Yoshinuma M, Akiyama T, Ashikawa N, Emoto M, Funaba H, Goto M, Ido T, Ikeda K, Inagaki S, Isobe M, Igami H, Itoh K, Kaneko O, Kawahata K, Kobuchi T, Masuzaki S, Matsuoka K, Minami T, Miyazawa J, Muto S, Nagayama Y, Nakamura Y, Nakanishi H, Narushima Y, Nishimura K, Nishiura M, Nishizawa A, Noda N, Ohdachi S, Oka Y, Osakabe M, Ohyabu N, Ozaki T, Peterson BJ, Sagara A, Saito K, Sakamoto R, Sato K, Sato M, Seki T, Shoji M, Sudo S, Tamura N, Toi K, Tokuzawa T, Tsumori K, Uda T, Watari T, Yamada I, Yokoyama M, Yoshimura Y, Motojima O, Beidler CD, Fujita T, Isayama A, Sakamoto Y, Takenaga H, Goncharov P, Ishii K, Sakamoto M, Murakami S, Notake T, Takeuchi N, Okajima S, Sasao M. Overview of Progress in LHD Experiments. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1229] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Igami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Minami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Muto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Sato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Uda
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - C. D. Beidler
- Max-Planck Institut fuer Plasmaphysik, Greifswald D-17491, Germany
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka 311-0193, Japan
| | - P. Goncharov
- Graduate University for Advanced Studies, School of Mathematical and Physical Science Department of Fusion Science, Hayama 240-0193, Japan
| | - K. Ishii
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - M. Sakamoto
- Kyushu University, Research Institute for Applied Mechanics Kasuga 816-8580, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - T. Notake
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - N. Takeuchi
- Nagoya University, Department of Energy Engineering and Science Nagoya 464-8603, Japan
| | - S. Okajima
- Chubu University, Kasugai, Aichi 487-8501, Japan
| | - M. Sasao
- Tohoku University, Graduate School of Engineering, Sendai 980-8579, Japan
| | | |
Collapse
|
31
|
Yamada H, Ida K, Murakami S, Watanabe KY, Ascasibar E, Brakel R, Dinklage A, Harris JH, Okamura S, Sano F, Stroth U, Inagaki S, Tanaka K, Goto M, Nishimura K, Narihara K, Morita S, Sakakibara S, Peterson BJ, Sakamoto R, Miyazawa J, Morisaki T, Osakabe M, Toi K, Tamura N, Ikeda K, Yamazaki K, Kawahata K, Kaneko O, Ohyabu N, Komori A, Motojima O. Configuration Effect on Energy Confinement and Local Transport in LHD and Contribution to the International Stellarator Database. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a543] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | | - R. Brakel
- Max-Planck-Institut für Plasmaphysik, D-17941 Greifswald, Germany
| | - A. Dinklage
- Max-Planck-Institut für Plasmaphysik, D-17941 Greifswald, Germany
| | - J. H. Harris
- Australian National University, Plasma Research Laboratory, Canberra, ACT 0200, Australia
| | - S. Okamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - F. Sano
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - U. Stroth
- University of Kiel, Institute of Experimental and Applied Physics, 24098 Kiel, Germany
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi Gifu-ken 509-5292, Japan
| | | |
Collapse
|
32
|
Shimozuma T, Yokoyama M, Ida K, Takeiri Y, Kubo S, Murakami S, Wakasa A, Idei H, Yoshimura Y, Notake T, Inagaki S, Tamura N, Toi K, Ohyabu N, Osakabe M, Ikeda K, Tsumori K, Oka Y, Nagaoka K, Kaneko O, Yamada I, Narihara K, Nagayam Y, Muto S, Tanaka K, Tokuzawa T, Morita S, Goto M, Yoshinuma M, Funaba H, Morisaki T, Watanabe KY, Miyazawa J, Mutoh T, Watari T, Ohkubo K. Improvement of Plasma Core Confinement Via Electron-Root Realization by Strongly Focused ECRH in LHD: Core Electron-Root Confinement. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10791] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Shimozuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - A. Wakasa
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - H. Idei
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Notake
- RIKEN, Tera-Photonics Laboratory, Aoba Sendai-City, Miyagi 980-0845, Japan
| | - S. Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - N. Tamura
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Nagayam
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Muto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
33
|
Shoji M, Masuzaki S, Kobayashi M, Goto M, Morisaki T, Yamada H, Komori A, Iwamae A, Sakaue A. Investigation of the Helical Divertor Function and the Future Plan of a Closed Divertor for Efficient Particle Control in the LHD Plasma Periphery. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-04] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - A. Iwamae
- Department of Mechanical Engineering and Science, Graduate School of Engineering Kyoto University, Kyoto 606-8501, Japan
| | - A. Sakaue
- Department of Mechanical Engineering and Science, Graduate School of Engineering Kyoto University, Kyoto 606-8501, Japan
| | | |
Collapse
|
34
|
Kobayashi M, Feng Y, Morita S, Masuzaki S, Ezumi N, Kobayashi T, Chowdhuri MB, Yamada H, Morisaki T, Ohyabu N, Goto M, Yamada I, Narihara K, Komori A, Motojima O. Transport Characteristics in the Stochastic Magnetic Boundary of LHD: Magnetic Field Topology and Its Impact on Divertor Physics and Impurity Transport. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10809] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Kobayashi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Feng
- Max-Planck-Institut für Plasmaphysik, EURATOM-IPP Association D-17491, Greifswald, Germany
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ezumi
- Nagano National College of Technology, Nagano 381-8550, Japan
| | - T. Kobayashi
- Nagano National College of Technology, Nagano 381-8550, Japan
| | - M. B. Chowdhuri
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | | |
Collapse
|
35
|
Sakamoto R, Yamada H, Kobayashi M, Miyazawa J, Ohdachi S, Morisaki T, Masuzaki S, Goto M, Funaba H, Yamada I, Ida K, Morita S, Peterson BJ, Ohyabu N, Komori A, Motojima O. Advanced Operational Regime with Internal Diffusion Barrier on LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10793] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | | |
Collapse
|
36
|
Morisaki T, Masuzaki S, Kobayashi M, Sakamoto R, Tanaka K, Narihara K, Funaba H, Feng Y, Sardei F, Ohyabu N, Komori A, Motojima O, Feng Y, Sardei F. Recent Results of LID Experiment on LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1238] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Feng
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - F. Sardei
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Feng
- Max-Planck-Institut für Plasmaphysik, EURATOM Association D-17941, Greifswald, Germany
| | - F. Sardei
- Max-Planck-Institut für Plasmaphysik, EURATOM Association D-17941, Greifswald, Germany
| | | |
Collapse
|
37
|
Affiliation(s)
- T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
38
|
Masuzaki S, Kobayashi M, Tokitani M, Ashikawa N, Hino T, Yamauchi Y, Nobuta Y, Yoshida N, Miyamoto M, Sakamoto R, Miyazawa J, Morisaki T, Ohyabu N, Yamada H, Komori A. Fuel Retention in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10818] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Masuzaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Tokitani
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Hino
- Hokkaido University, Sapporo 060-8628, Japan
| | - Y. Yamauchi
- Hokkaido University, Sapporo 060-8628, Japan
| | - Y. Nobuta
- Hokkaido University, Sapporo 060-8628, Japan
| | - N. Yoshida
- Research Institute for Applied Mechanics, Kyushu University, Fukuoka 816-8580, Japan
| | | | - R. Sakamoto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
39
|
Miyazawa J, Yamada H, Sakamoto R, Funaba H, Watanabe KY, Sakakibara S, Ida K, Goto M, Morisaki T, Murakami S, Inagaki S. Characteristics of the Global Energy Confinement and Central Pressure in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10790] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Miyazawa
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - S. Murakami
- Kyoto University, Department of Nuclear Engineering, Kyoto 606-8501, Japan
| | - S. Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | | |
Collapse
|
40
|
Morisaki T, Masuzaki S, Sakamoto R, Kobayashi M, Ohyabu N, Yamada H, Komori A. Local Island Divertor Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10810] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
41
|
Seki T, Mutoh T, Kumazawa R, Saito K, Nakamura Y, Sakamoto M, Watanabe T, Kubo S, Shimozuma T, Yoshimura Y, Igami H, Ohkubo K, Takeiri Y, Oka Y, Tsumori K, Osakabe M, Ikeda K, Nagaoka K, Kaneko O, Miyazawa J, Morita S, Narihara K, Shoji M, Masuzaki S, Goto M, Morisaki T, Peterson BJ, Sato K, Tokuzawa T, Ashikawa N, Nishimura K, Funaba H, Chikaraishi H, Takeuchi N, Notake T, Ogawa H, Torii Y, Shimpo F, Nomura G, Yokota M, Takahashi C, Kato A, Takase Y, Kasahara H, Ichimura M, Higaki H, Zhao YP, Kwak JG, Yamada H, Kawahata K, Ohyabu N, Ida K, Nagayama Y, Noda N, Watari T, Komori A, Sudo S, Motojima O. Study of Long-Pulse Plasma Experiment Using ICRF Heating in LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1234] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Seki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | | - T. Watanabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Igami
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Takeuchi
- Nagoya University, Faculty of Engineering, Nagoya 464-8601, Japan
| | - T. Notake
- Nagoya University, Faculty of Engineering, Nagoya 464-8601, Japan
| | - H. Ogawa
- Graduate University for Advanced Studies, Hayama 240-0162, Japan
| | - Y. Torii
- Kyoto University, Institute of Advanced Energy, Uji 611-0011, Japan
| | - F. Shimpo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - G. Nomura
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yokota
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - C. Takahashi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Kato
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | | | | | | - H. Higaki
- University of Tsukuba, Tsukuba, Japan
| | - Y. P. Zhao
- Institute of Plasma Physics, Academia Sinica, Hefei 230031, P.R. China
| | - J. G. Kwak
- Korea Atomic Energy Research Institute, Daejeon 305-600, Korea Rep
| | - H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
42
|
König R, Grigull P, McCormick K, Feng Y, Ehmler H, Gadelmeier F, Giannone L, Hildebrandt D, Kisslinger J, Klinger T, Naujoks D, Ramasubramanian N, Renner H, Sardei F, Thomsen H, Wagner F, Wenzel U, Werner A, Komori A, Masuzaki S, Matsuoka K, Mioduszewski P, Morisaki T, Obiki T, Ohyabu N. Divertors for Helical Devices: Concepts, Plans, Results, and Problems. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a551] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. König
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - P. Grigull
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - K. McCormick
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - Y. Feng
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - H. Ehmler
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - F. Gadelmeier
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - L. Giannone
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - D. Hildebrandt
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - J. Kisslinger
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - T. Klinger
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - D. Naujoks
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - N. Ramasubramanian
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - H. Renner
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - F. Sardei
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - H. Thomsen
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - F. Wagner
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - U. Wenzel
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - A. Werner
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - A. Komori
- National Institute for Fusion Science Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Mioduszewski
- Oak Ridge National Laboratory, P.O. Box 2008, M.S. 6169, Oak Ridge, Tennessee 37831
| | - T. Morisaki
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| | - T. Obiki
- Kyoto University, Institute of Advanced Energy, Gakasho, Uji, Japan
| | - N. Ohyabu
- Max-Planck-Institut für Plasmaphysik EURATOM Association, D-17491 Greifswald, Germany
| |
Collapse
|
43
|
Yamada H, Kawahata K, Mutoh T, Ohyabu N, Takeiri Y, Imagawa S, Ida K, Mito T, Nagayama Y, Shimozuma T, Watanabe KY, Kobayashi M, Kumazawa R, Masuzaki S, Morisaki T, Miyazawa J, Nagaoka K, Narushima Y, Sakakibara S, Sakamoto R, Toi K, Yokoyama M, Kaneko O, Komori A, Motojima O. Progress in the Integrated Development of the Helical System. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a10789] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - O. Motojima
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | |
Collapse
|
44
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
45
|
Masuzaki S, Morisaki T, Shoji M, Kubota Y, Watanabe T, Kobayashi M, Miyazawa J, Goto M, Morita S, Peterson BJ, Ohyabu N, Komori A, Motojima O, Ogawa H. Overview and Future Plan of Helical Divertor Study in the Large Helical Device. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1257] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Masuzaki
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - Y. Kubota
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - M. Kobayashi
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - A. Komori
- Graduate University for Advanced Studies, Hayama 240-0163, Japan
| | - O. Motojima
- National Institute for Fusion Science 322-6 Oroshi-cho, Toki Gifu 509-5292, Japan
| | - H. Ogawa
- Graduate University for Advanced Studies, Hayama 240-0163, Japan
| | | |
Collapse
|
46
|
Goto W, Kashiwagi S, Asano Y, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Abstract P6-09-25: Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Accumulating evidence shows that circulating tumor cells (CTC) are linked to metastatic relapse and are regarded as a prognostic marker for human cancer. It was reported that CTC clusters (CTCc) have more metastatic potential than single CTC. Lately, studies also show that the high expression of plakoglobin, a cell adhesion protein, within the primary tumor are positively associated with CTCc in breast cancer patients. In addition, it is thought that insufficient expression of plakoglobin could promote epithelial-mesenchymal transition (EMT). In this study, we investigated the correlation between plakoglobin expression and survival of breast cancer.
Materials and Methods:A total of 126 patients with resectable early-stage breast cancer were treated with neoadjuvant chemotherapy (NAC). All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m2 fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m2 paclitaxel administered weekly. The expression of plakoglobin were identified by immunohistochemical staining properties in cell membrane. Staining with plakoglobin (clone 4C12) was scored according to the percentage of cells that stained positively: low, 0-25%; medium, 26-75%; high, >75%. We investigated the correlation between the plakoglobin expression in primary tumor specimen and clinical outcomes including overall-survival (OS), disease-free-survival (DFS), distant-metastasis-free-survival (DMFS), the efficacy of NAC. And we examined the relation between the expression of plakoglobin and E-cadherin, EMT marker.
Results: The patient with high plakoglobin expression had significantly worse OS (p=0.021, log-rank) and DFS (p=0.015, log-rank), DMFS (p=0.040, log-rank). And the plakoglobin expression had no correlation with pathological complete response (pCR) rate (p=0.596). Also, there was not a statistically significant relationship between the plakoglobin expression and other clinicopathological parameters including tumor size (p=0.708), lymph node status (p=0.479), subtype (p=0.413), nuclear grade (p=0.642), Ki67 (p=0.202), tumor infiltrating lymphocytes (p=0.828). On univariate analysis with respect to distal metastasis, high plakoglobin expression showed worse prognosis than low plakoglobin expression (p=0.013, hazard ratio=4.221). And multivariate analysis found the same result (p=0.015, hazard ratio=4.070). In addition, there was a significant relationship between the expression of plakoglobin and E-cadherin (p=0.023).
Conclusions: Plakoglobin expression is an independent prognostic factor in the patients with breast cancer; particularly for DMFS, and this mechanism related to EMT.Background: Accumulating evidence shows that circulating tumor cells (CTC) are linked to metastatic relapse and are regarded as a prognostic marker for human cancer. It was reported that CTC clusters (CTCc) have more metastatic potential than single CTC. Lately, studies also show that the high expression of plakoglobin, a cell adhesion protein, within the primary tumor are positively associated with CTCc in breast cancer patients. In addition, it is thought that insufficient expression of plakoglobin could promote epithelial-mesenchymal transition (EMT). In this study, we investigated the correlation between plakoglobin expression and survival of breast cancer.
Materials and Methods:A total of 126 patients with resectable early-stage breast cancer were treated with neoadjuvant chemotherapy (NAC). All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m2 fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m2 paclitaxel administered weekly. The expression of plakoglobin were identified by immunohistochemical staining properties in cell membrane. Staining with plakoglobin (clone 4C12) was scored according to the percentage of cells that stained positively: low, 0-25%; medium, 26-75%; high, >75%. We investigated the correlation between the plakoglobin expression in primary tumor specimen and clinical outcomes including overall-survival (OS), disease-free-survival (DFS), distant-metastasis-free-survival (DMFS), the efficacy of NAC. And we examined the relation between the expression of plakoglobin and E-cadherin, EMT marker.
Results: The patient with high plakoglobin expression had significantly worse OS (p=0.021, log-rank) and DFS (p=0.015, log-rank), DMFS (p=0.040, log-rank). And the plakoglobin expression had no correlation with pathological complete response (pCR) rate (p=0.596). Also, there was not a statistically significant relationship between the plakoglobin expression and other clinicopathological parameters including tumor size (p=0.708), lymph node status (p=0.479), subtype (p=0.413), nuclear grade (p=0.642), Ki67 (p=0.202), tumor infiltrating lymphocytes (p=0.828). On univariate analysis with respect to distal metastasis, high plakoglobin expression showed worse prognosis than low plakoglobin expression (p=0.013, hazard ratio=4.221). And multivariate analysis found the same result (p=0.015, hazard ratio=4.070). In addition, there was a significant relationship between the expression of plakoglobin and E-cadherin (p=0.023).
Conclusions: Plakoglobin expression is an independent prognostic factor in the patients with breast cancer; particularly for DMFS, and this mechanism related to EMT.
Citation Format: Goto W, Kashiwagi S, Asano Y, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-25.
Collapse
Affiliation(s)
- W Goto
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Kashiwagi
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Asano
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Takada
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Takashima
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Morisaki
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Noda
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - N Onoda
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohsawa
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Hirakawa
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohira
- Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
47
|
Kashiwagi S, Asano Y, Goto W, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Abstract P3-04-20: Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-04-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer with distant metastasis at first presentation (stage IV disease) is often encountered in the outpatient department. With recent advances in multimodal therapies for breast cancer, long-term survival can now be expected even in stage IV breast cancer with distant metastasis. However, a goal in treating metastatic disease is prolongation of survival while maintaining good quality of life (QOL). Endocrine therapy is suitable for this purpose.The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. These immune responses can be evaluated with tumor-infiltrating lymphocytes (TILs), which has frequently been verified clinically. In the present study, we hypothesized that TILs would be useful as predictive marker of the therapeutic effect in endocrine therapy as well. In this study, the prediction of the therapeutic effect by TILs in endocrine therapy for stage IV breast cancer was clinically verified.
Materials and Methods:Data from 40 patients who underwent endocrine therapy as the initial drug therapy for stage IV breast cancer were used. The correlation between TILs evaluated according to the standard method, and prognosis, including the efficacy of endocrine therapy, was investigated retrospectively. Patients with 350% lymphocytic infiltration were considered to have lymphocyte-predominant breast cancer (LPBC).
Results:Among all 40 patients, TIL levels were high in 13 (32.5%) and low in 27 (67.5%) patients. Nine patients (22.5%) had LPBC, and 31 patients (77.5%) had non-LPBC. Investigation of the clinical pathological features of patients showed no significant differences between the high TIL and low TIL groups. There were also no significant differences between LPBC and non-LPBC patients. An analysis of outcomes comparing the high TIL and low TIL groups showed no prolongation in progression-free survival (PFS) (p=0.171, log-rank), time to treatment failure (TTF)(p=0.054), or overall survival (OS) (p=0.641). LPBC patients had significant prolongations of PFS (p=0.005), TTF (p=0.001), and OS (p=0.027) compared to non-LPBC patients. On receiver operating characteristic (ROC) curve analyses, results were better with LPBC (AUC: 0.700) than with TILs (AUC: 0.606).
Conclusion: The present findings suggest that a high level of lymphocytic infiltration in the tumor stroma may serve as a predictor of the therapeutic effect of endocrine therapy for patients with stage IV ER-positive breast cancer.
Citation Format: Kashiwagi S, Asano Y, Goto W, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-20.
Collapse
Affiliation(s)
- S Kashiwagi
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Asano
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - W Goto
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Takada
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Takashima
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Morisaki
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Noda
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - N Onoda
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohsawa
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Hirakawa
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohira
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
48
|
Asano Y, Kashiwagi S, Goto W, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Abstract P2-05-05: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. Thus, the importance of inhibiting and improving the tumor immune microenvironment is now recognized. These immune responses can be evaluated with tumor-infiltrating lymphocytes (TILs), which has frequently been verified clinically. On the other hand, residual cancer burden (RCB) evaluation has been shown to be a useful predictor of survival after neoadjuvant chemotherapy (NAC). In this study, RCB and TILs evaluations were combined to produce an indicator that we have termed “RCB-TILs”, and its clinical application to NAC for breast cancer was verified by subtype-stratified analysis.
Materials and Methods:A total of 177 patients with resectable early-stage breast cancer were treated with NAC.The correlation between TILs evaluated according to the standard method, and prognosis, including the efficacy of NAC, was investigated retrospectively. The RCB was calculated using the Residual Cancer Burden Calculator on the website of the MD Anderson Cancer Center. The RCB and TILs evaluations were combined to create the “RCB-TILs”. Patients who were RCB-positive and had high TILs were considered RCB-TILs-positive, and all other combinations were RCB-TILs-negative.
Results: Univariable analysis of patients with high TILs found that this contributed significantly to prolonging DFS in all patients (p = 0.022, hazard ratio = 0.420), TNBC patients (p = 0.004, hazard ratio = 0.177), and HER2BC patients (p = 0.026, hazard ratio = 0.123). For HRBC patients, however, high TILs did not contribute to survival (p = 0.990, hazard ratio = 0.992). Being RCB-TILs-positive, however, contributed significantly to prolonging DFS in all patients (p < 0.001, hazard ratio = 0.181), TNBC patients (p < 0.001, hazard ratio = 0.099), HER2BC patients (p = 0.026, hazard ratio = 0.123), and HRBC patients (p = 0.039, hazard ratio = 0.258). On multivariable analysis, being RCB-TILs-positive was an independent factor for recurrence after NAC in all patients (p < 0.001, hazard ratio = 0.048), TNBC patients (p = 0.018, hazard ratio = 0.041), HER2BC patients (p = 0.036, hazard ratio = 0.134), and HRBC patients (p = 0.002, hazard ratio = 0.081).
Conclusion: The results of the present study suggest that RCB-TILs is a significant predictor for breast cancer recurrence after NAC and may be a more sensitive indicator than TILs alone.
Citation Format: Asano Y, Kashiwagi S, Goto W, Takada K, Takashima T, Morisaki T, Noda S, Onoda N, Ohsawa M, Hirakawa K, Ohira M. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-05.
Collapse
Affiliation(s)
- Y Asano
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Kashiwagi
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - W Goto
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Takada
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Takashima
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Morisaki
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Noda
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - N Onoda
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohsawa
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Hirakawa
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Ohira
- Osaka City University Graduate School of Medicine, Osaka, Japan; Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
49
|
Takeshima F, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Machida H, Matsushima K, Minami H, Akazawa Y, Yamaguchi N, Ohnita K, Isomoto H, Ueno M, Nakao K. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016; 16:82. [PMID: 27472988 PMCID: PMC4966785 DOI: 10.1186/s12876-016-0501-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Accepted: 07/26/2016] [Indexed: 02/08/2023] Open
Abstract
Background There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing postoperative recurrence in Crohn's disease (CD) in Asian real practice settings. We conducted a Japanese multicenter retrospective observational study. Methods We evaluated patients with CD who were treated with ADA at 11 medical institutions in Japan to investigate the clinical efficacy of remission up to 52 weeks and the associated factors to achieve remission with a CD Activity Index (CDAI) < 150. The effects of preventing postoperative recurrence were also evaluated. Results In 62 patients, the remission rates were 33.9, 74.2, 75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks, respectively. Although 10 patients discontinued treatment due to primary nonresponse, secondary nonresponse, or adverse events, the ongoing treatment rate at 52 weeks was 83.9 %. Comparison of remission and non-remission on univariate analysis identified colonic type and baseline CDAI value as significant associated factors (P < 0.05). In 16 patients who received ADA to prevent postoperative recurrence, the clinical remission maintenance rate was 93.8 % and the mucosal healing rate was 64.3 % during a mean postoperative follow-up period of 32.3 months. Conclusions ADA effectively induced remission and prevented postoperative recurrence in patients with CD in a real practice setting.
Collapse
Affiliation(s)
- Fuminao Takeshima
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.
| | - Daisuke Yoshikawa
- Department of Gastroenterology and Hepatology, Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo City, Nagasaki, 857-8511, Japan
| | - Syuntaro Higashi
- Department of Gastroenterology, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Ohmura City, Nagasaki, 856-8562, Japan
| | - Tomohito Morisaki
- Department of Gastroenterology and Hepatology, National Hospital Organization Ureshino Medical Center, 2436 Ureshino-cho, Ureshino City, Saga, 843-0393, Japan
| | - Hidetoshi Oda
- Department of Gastroenterology and Hepatology, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo City, Nagasaki, 857-1195, Japan
| | - Maho Ikeda
- Department of Internal Medicine, Kouseikai Hospital, 1-3-12 Hayama, Nagasaki City, Nagasaki, 852-8053, Japan
| | - Haruhisa Machida
- Department of Internal Medicine, Shunkaikai Inoue Hospital, 6-12 Takara-machi, Nagasaki City, Nagasaki, 850-0045, Japan
| | - Kayoko Matsushima
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Hitomi Minami
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Yuko Akazawa
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Naoyuki Yamaguchi
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Ken Ohnita
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Hajime Isomoto
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| | - Masato Ueno
- Integrated Marketing Department, Eisai Co., Ltd., 13-1 Nishigoken-cho, Shinjuku-ku, Tokyo, 162-0812, Japan
| | - Kazuhiko Nakao
- Department of Gastroenterology and Hepatology, Graduate School of Biomedical Science, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan
| |
Collapse
|
50
|
Kashiwagi S, Asano Y, Goto W, Morisaki T, Noda S, Takashima T, Onoda N, Hirakawa K. Abstract P3-07-33: Prediction of the treatment response to neoadjuvant chemotherapy in breast cancer by subtypes using tumor-infiltrating lymphocytes. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Monitoring the host immunological response to cancer in the microenvironment of the interaction between tumor and the body plays an important role in predicting treatment response and outcomes. Recent interest has focused on the morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) and on the evidence showing their clinical relevance. Meanwhile, no consensus has yet been reached on standard methods for pathological evaluation of TILs. Therefore, methods of evaluation have differed in reports to date showing the clinical relevance of TILs. An International Working Group (2014) announced recommendations for evaluating TILs in an effort to improve consistency and reproducibility. In this study, the clinical validity and utility of TILs in NAC were investigated based on this recommendation with a stratified analysis by BC subtypes. Changes in TILs after recurrence, which have seldom been reported to date, are also discussed.
Experimental Design: TILs was evaluated in 177 patients with breast cancer treated with NAC and subsequent curative surgery. All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m2 fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m2 paclitaxel administered weekly. Forty-five patients had HER2-positive breast cancer and were additionally administered weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab during paclitaxel treatment. The correlation between TILs evaluated according to the standard method, and prognosis, including the efficacy of NAC, was investigated retrospectively.
Results: In the 96 high-TIL group, compared to the 81 low-TIL group, triple-negative breast cancer (TNBC) (p < 0.001) and HER2-enriched (p = 0.040) were significantly more frequent, and the pathological complete response (pCR) rate were significantly higher (p = 0.003). On multivariate analysis also demonstrated that high-TIL status was an independent factor to indicate significantly more favorable prognosis of the patients compared with low-TIL status (p = 0.036, HR = 0.45). Among the 61 TNBC and the 36 HER2-enriched patients, the pCR rate was significantly higher in the high-TIL group than in the low-TIL group (p = 0.013) (p = 0.014). On multivariate analysis also showed that high-TIL status was an independent factor to predict the favorable prognosis (p = 0.023, HR = 0.24) (p = 0.036, HR = 0.13). Biopsy specimens from local recurrence after successful NAC frequently showed decreased TILs.
Conclusion: TILs may be a biomarker to predict treatment response to NAC in patients with TNBC and HER2-enriched subtypes of BC. A decrease in TILs may also be associated with tumor recurrence.
Citation Format: Kashiwagi S, Asano Y, Goto W, Morisaki T, Noda S, Takashima T, Onoda N, Hirakawa K. Prediction of the treatment response to neoadjuvant chemotherapy in breast cancer by subtypes using tumor-infiltrating lymphocytes. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-33.
Collapse
Affiliation(s)
- S Kashiwagi
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Y Asano
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - W Goto
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Morisaki
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - S Noda
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Takashima
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - N Onoda
- Osaka City University Graduate School of Medicine, Osaka, Japan
| | - K Hirakawa
- Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|